What is subclinical hypothyroidism, and does it need treating?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
Subclinical hypothyroidism means TSH is above the reference range while free T4 is still normal. Most cases with TSH under 10 mIU/L do not need levothyroxine, and roughly half of mildly raised values normalise on their own. Treatment is generally recommended when TSH is above 10 mIU/L, in pregnancy or when trying to conceive, and sometimes with positive TPO antibodies.
Subclinical hypothyroidism is a laboratory pattern, not a symptom set: TSH is above the laboratory upper limit while free T4 remains inside its normal range. It is common, affecting 4.3 percent of the United States population in the NHANES III survey. The important clinical question is not whether the label fits but whether treating changes anything, and for most people with a mildly raised TSH the honest answer is that it does not.
Repeat the test before treating
A single raised TSH is often not reproducible. Recovery from illness, laboratory variation, time of day and transient thyroiditis all push TSH up temporarily. Published cohorts show substantial spontaneous normalisation: roughly half of adults aged 55 and over with a TSH under 10 mIU/L returned to normal over about two and a half years, and the likelihood was highest when TSH was below 7 mIU/L with negative TPO antibodies. Repeating TSH and free T4 after six to twelve weeks avoids committing people to lifelong medication for a blip.
Who actually benefits from levothyroxine
Treatment is standard when TSH exceeds 10 mIU/L, where the association with coronary heart disease is most consistent. Below that, the evidence for symptom benefit is weak. The TRUST trial randomised 737 adults aged 65 and over with TSH between 4.6 and 19.99 mIU/L to levothyroxine or placebo. TSH fell from 6.40 to 3.63 mIU/L in the treated group, and after twelve months there was no clinical difference in the hypothyroid symptoms score or the tiredness score. That is a well-conducted trial showing that normalising the number did not change how people felt.
Where treatment is clearly indicated
Pregnancy and preconception are different. The 2026 American Thyroid Association pregnancy guideline recommends levothyroxine when TSH exceeds 10 mU/L regardless of trimester, and treatment of mild elevations is considered in early first trimester, after confirmatory retesting within four to six weeks. Younger adults with symptoms, positive TPO antibodies and a rising TSH are also reasonable candidates for a defined trial with a stop rule.
| Situation | Usual approach |
|---|---|
| TSH above 10 mIU/L, confirmed | Treat with levothyroxine |
| TSH 4.5 to 10 mIU/L, no symptoms, age over 70 | Monitor, do not treat reflexively |
| TSH 4.5 to 10 mIU/L, symptoms, TPO positive, under 65 | Time-limited trial with a clear endpoint |
| Pregnant or actively trying to conceive | Lower threshold to treat, retest early |
If you are offered levothyroxine for a mildly raised TSH, ask for the test to be repeated first, ask what specific symptom is expected to improve, and agree in advance when the trial will be judged a failure and stopped.
The clinical detail
Annual progression from subclinical to overt hypothyroidism runs roughly 2 to 6 percent, rising to about 3 to 8 percent with positive TPO antibodies. Higher baseline TSH, female sex and antibody positivity predict progression.
TSH rises with age in healthy people, so a fixed adult cut-off overdiagnoses older patients. A 2025 Cleveland Clinic Journal of Medicine review describes a target TSH of 4 to 6 mIU/L for patients aged 70 to 80 and a wait-and-see approach for TSH at or below 10 mIU/L beyond age 80. Where a trial is undertaken, typical starting doses are 25 to 50 mcg daily rather than weight-based full replacement, with TSH rechecked 6 to 8 weeks later, consistent with the levothyroxine label. Stop the trial if the target symptom is unchanged after three to six months at a normalised TSH.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism (TRUST trial). New England Journal of Medicine. PMID 28402245
- Subclinical Hypothyroidism. StatPearls, National Library of Medicine
- American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum. American Thyroid Association. PMID 42219800
- Most elderly patients with subclinical hypothyroidism do not need to be treated. Cleveland Clinic Journal of Medicine. DOI 10.3949/ccjm.92a.24098
- Serum TSH, T4, and Thyroid Antibodies in the United States Population (NHANES III). Journal of Clinical Endocrinology and Metabolism. PMID 11836274
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.